tolfenamic acid
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT02159248)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
- Cyclooxygenase-1INHIBITOR
PTGS1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(Cl)cccc1Nc1ccccc1C(=O)O- Mol. weight
- 261.71 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL121626 ↗
Also known as
- bifenac
- clotam
- clotam
- clotam
- clotam rapid
- gea 6414
- n-(3-chloro-2-methylphenyl)anthranilic acid
- n-(3-chloro-o-tolyl)anthranilic acid
- pharmacia brand of tolfenamic acid
- provalis brand of tolfenamic acid
- rociclyn
- tolfedine
- tolfenamic acid
- tolfenamic acid
- tolfenamic acid
- tolfenamic acid
- tolfenamic acid
- tolfenamic acid
- tolfenamic acid
- tolfenamic acid
- tolfine
- zambon brand of tolfenamic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04253132 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2021 | NeuroTau, Inc., The Cleveland Clinic |
| NCT02159248 | Phase 1 | Mar 1, 2014 | Orlando Health |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeuroTau, Inc. | For profit | 1 | 1 | 1 | 2021 |
| Orlando Health | Academic/Hospital | 1 | 1 | 1 | 2014 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1